Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
February 17, 2021 07:30 ET
|
Otonomy, Inc.
Presentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing lossSupportive preclinical data to be presented for OTO-825 gene therapy and OTO-510 otoprotection...
Otonomy Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
February 11, 2021 16:17 ET
|
Otonomy, Inc.
OTIVIDEX® Phase 3 trial results in Ménière’s disease expected by end of FebruaryOTO-313 Phase 2 trial in tinnitus planned to start in first quarter of 2021 with top-line results expected in...
Otonomy to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
February 04, 2021 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy to Participate in the H.C. Wainwright BioConnect 2021 Virtual Conference
January 05, 2021 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Provides Update on OTIVIDEX® and OTO-313 Programs
November 30, 2020 07:30 ET
|
Otonomy, Inc.
FDA’s review confirms use of Negative Binomial model for analysis of primary endpoint in ongoing OTIVIDEX Phase 3 trial in Ménière’s disease; results still expected in first quarter of 2021Company...
Otonomy to Participate in Two Upcoming Investor Conferences
November 16, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 04, 2020 16:17 ET
|
Otonomy, Inc.
Enrollment completed in Phase 3 clinical trial of OTIVIDEX® in Ménière’s disease with results expected in the first quarter of 2021Positive results reported for Phase 1/2 clinical trial of OTO-313 in...
Otonomy to Report Third Quarter 2020 Financial Results and Provide Corporate Update
October 28, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Completes Patient Enrollment for Phase 3 Trial of OTIVIDEX® in Ménière’s Disease
October 02, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy to Participate in Four Upcoming Investor Conferences
September 02, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...